Rockefeller Financial Services Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 20.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 104,974 shares of the biopharmaceutical company’s stock after buying an additional 17,718 shares during the period. Rockefeller Financial Services Inc.’s holdings in Pfizer were worth $3,696,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of the stock. Bloom Tree Partners LLC purchased a new position in Pfizer during the first quarter worth about $35,682,000. State of Alaska Department of Revenue increased its position in Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock worth $13,093,000 after buying an additional 37,647 shares during the period. BlackRock Group LTD increased its position in Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the period. Charter Trust Co. increased its position in Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock worth $13,306,000 after buying an additional 15,510 shares during the period. Finally, Franklin Resources Inc. increased its position in Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the period. Institutional investors and hedge funds own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.31% on Friday, hitting $32.66. The company’s stock had a trading volume of 15,569,339 shares. The stock has a 50-day moving average price of $34.02 and a 200 day moving average price of $34.27. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The firm has a market cap of $198.10 billion, a price-to-earnings ratio of 28.95 and a beta of 0.86.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the company posted $0.56 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. The ex-dividend date is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.
PFE has been the topic of a number of research reports. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Bank of America Corp. set a $40.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, August 22nd. Jefferies Group lowered their target price on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Credit Suisse Group AG reiterated an “outperform” rating and set a $40.00 target price on shares of Pfizer in a research report on Monday, August 22nd. Finally, Argus reiterated a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Tuesday, October 4th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $38.59.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.